AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36204243
Drug: Venglustat 8
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venglustat 8 mg once daily
Trial: 36481125
Drug: Venglustat 15
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venglustat 15 mg once daily
Trial: 36204243
Drug: Venglustat (preferred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venglustat (preferred dose based on stage 1 safety data)
Trial: 36204820
Drug: Ciltacabtagene autoleucel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene autoleucel (cilta-cel) at a targeted dose of 0.75 × 10^6 CAR T cells/kg
Trial: 36205514
Drug: AVT02 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT02 administered subcutaneously via autoinjector (AI), 40 mg, for 8 weeks
Trial: 36205514
Drug: AVT02 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT02 administered via prefilled syringe in the extension phase
Trial: 36206041
Drug: Pemigatinib, 13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemigatinib, 13.5 mg orally once daily for 14 consecutive days, followed by 7 days off therapy
Trial: 36206189
Drug: FLASH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLASH therapy (8 Gy in a single fraction delivered at ≥40 Gy per second)
Trial: 36206189
Drug: FLASH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLASH therapy
Trial: 36207609
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy (PtCT) in gBRCA1/2m carriers (N=300)
Trial: 36207609
Drug: Non-platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2m carriers (N=300)
Trial: 36207609
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy (PtCT) in gBRCA1/2wt patients (N=922)
Trial: 36207609
Drug: Non-platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2wt patients (N=922)
Trial: 36209118
Drug: Study medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication (all types)
Trial: 36209118
Drug: Treatment guidelines
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment guidelines adherence
Trial: 36209441
Drug: FIL200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL200 mg
Trial: 36209441
Drug: FIL100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL100 mg
Trial: 36210252
Drug: Altruism-tailored educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altruism-tailored educational intervention (spoken and written communication) highlighting altruistic benefits of accepting the seasonal influenza vaccine.
Trial: 36210299
Drug: sEphB4-HSA 1000
RxNorm normalized name: 125 I HSA
DrugBank: Albumin iodinated I-125 serum (DB09429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sEphB4-HSA 1000 mg IV administered every 2 weeks, extending to 3 weeks starting from cycle 7
Trial: 36211588
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitor (alirocumab)
Trial: 36211944
Drug: Ad libitum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad libitum drinking of a cool sport drink (237 mL every 15-20 min)
Trial: 36212652
Drug: Aricept and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aricept and Sodium Oligomannate (previous treatments)
Trial: 36212980
Drug: Intravesical Ty21a
RxNorm normalized name: Typhoid Vaccine Live Ty21a
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical Ty21a treatment
Trial: 36212980
Drug: Standard BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BCG treatment
Trial: 36213913
Drug: Isha Kriya
RxNorm normalized name: CAMPHOR, (-)- 1 g in 100 g TOPICAL PATCH [iShancare Back Pain Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isha Kriya meditation practice, performed daily for 6 weeks.
Trial: 36214278
Drug: Eating disorders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eating disorders (ED) treatment
Trial: 36215065
Drug: Less intense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intense treatment for breast cancer
Trial: 36215115
Drug: Color flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Color flow Doppler ultrasound with 1 mL normal saline injection
Trial: 36215115
Drug: Color flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Color flow Doppler ultrasound with 1 mL air/saline mixture
Trial: 36215232
Drug: Subcutaneous infusion
RxNorm normalized name: subcutaneous infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infusion of 235 ml isotonic saline containing a technetium-99m pertechnetate tracer
Trial: 36215912
Drug: High Drug
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Drug Use class
Trial: 36269898
Drug: Ciltacabtagene autoleucel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene autoleucel (cilta-cel) infusion
Trial: 36216013
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of BNT162b2
Trial: 36216013
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of BNT162b2
Trial: 36216013
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of BNT162b2 (less than 3 months after third dose)
Trial: 36216013
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of BNT162b2 (3 months or more after third dose)
Trial: 36217101
Drug: HSK3486 (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 (IV bolus dose of 0.4 mg/kg and maintenance infusion of 0.4 mg/kg/h)
Trial: 36219274
Drug: Osilodrostat; median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osilodrostat; median average dose was 10.6 mg/day (1.1-47.9)
Trial: 36219388
Drug: Long-acting β2-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β2-agonists (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC)
Trial: 36219705
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of sulfadoxine-pyrimethamine
Trial: 36219705
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of dihydroartemisinin-piperaquine (DP)
Trial: 36219705
Drug: Monthly DP
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly DP during pregnancy
Trial: 36219705
Drug: Monthly DP
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly DP from 2 to 24 months of age
Trial: 36220152
Drug: Once-weekly 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly 300 mg marstacimab
Trial: 36220152
Drug: Once-weekly 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly 150 mg marstacimab (after a 300 mg loading dose)
Trial: 36220196
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance assessed by the insulin sensitivity index (ISI)
Trial: 36220315
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life and daily physical activity assessment in children and adolescents with IBD
Trial: 36220852
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus aromatase inhibitor (AI)
Trial: 36221952
Drug: FOLFIRINOX chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX chemotherapy followed by gemcitabine-based chemoradiation
Trial: 36223060
Drug: Halobetasol Proprionate
RxNorm normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol Proprionate 0.01% plus Tazarotene 0.045% (HP/Taz) lotion
Trial: 36223228
Drug: ACM-Beta spike
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACM-Beta spike vaccine
Trial: 36223228
Drug: ACM-WT spike
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACM-WT spike vaccine
Trial: 36223228
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) immunization
Trial: 36223228
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) immunization
Trial: 36223228
Drug: ACM-polymersome-based Covid-19
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACM-polymersome-based Covid-19 vaccine
Trial: 36223740
Drug: PARP inhibitor
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitor olaparib
Trial: 36223740
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CD47 antibodies and olaparib
Trial: 36223961
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) - single intravenous infusion of 375 mg/m²
Trial: 36223961
Drug: Standardised corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised corticosteroid treatment
Trial: 36224176
Drug: Pembrolizumab, trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, trastuzumab, and doublet chemotherapy
Trial: 36226495
Drug: Mivavotinib (TAK-659)
RxNorm normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivavotinib (TAK-659) 140 mg QD
Trial: 36226495
Drug: Mivavotinib (TAK-659)
RxNorm normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivavotinib (TAK-659) 60 mg BID
Trial: 36228112
Drug: Topical bexarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bexarotene
Trial: 36228644
Drug: Single-dose carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy (30 Gy in 15 fractions for stage IIA and 36 Gy in 18 fractions for stage IIB)
Trial: 36228644
Drug: Single-dose carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy
Trial: 36228746
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1)
Trial: 36228746
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with 70 Gy intensity modulated radiation therapy and every 3-week cisplatin (arm 2)
Trial: 36228746
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with 70 Gy intensity modulated radiation therapy and cetuximab (arm 3)
Trial: 36229024
Drug: Probiotics (Actiregularis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Actiregularis, 5×10^6) added to the diet of mothers once daily for 15 days
Trial: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan (Sac/Val) - Low Dose (112 mg)
Trial: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan (Sac/Val) - Moderate Dose (342 mg)
Trial: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan (Sac/Val) - High Dose (379 mg)
Trial: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan (Sac/Val) - All doses
Trial: 36229741
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants in T2DM patients
Trial: 36229741
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants in normo-glycemic patients
Trial: 36229741
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants (general)
Trial: 36229853
Drug: DZD2269 (A2aR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZD2269 (A2aR antagonist)
Trial: 36229853
Drug: DZD2269 (A2aR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZD2269 (A2aR antagonist) in combination with immune checkpoint inhibitors, radiotherapy, or chemotherapy
Trial: 36230640
Drug: Intensified NILG-AML
RxNorm normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified NILG-AML 01/00 protocol (high dose of ARAC plus idarubicin consolidation)
Trial: 36230669
Drug: Oral swab
RxNorm normalized name: Moi-Stir, oral swab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral swab assessment before RT
Trial: 36233712
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (6 weekly sessions)
Trial: 36233717
Drug: Invasive endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive endovascular treatment
Trial: 36237914
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (SGLT2-i)
Trial: 36237914
Drug: Non-SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-SGLT2 inhibitors (control group)
Trial: 36238465
Drug: Maternal-infant biological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal-infant biological samples (blood, feces, saliva, urine, and breast milk) collected during pregnancy and the first year of life.
Trial: 36239199
Drug: Dextromethorphan 15
RxNorm normalized name: dextromethorphan 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 15 mg t.i.d.
Trial: 36239199
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide inhaler 20 µg 2 puffs t.i.d.
Trial: 36239199
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of honey t.i.d.
Trial: 36239473
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 30 mg/m2 on day 1 combined with ifosfamide (IFO) 1.8 g/m2 on days 1-5 every 21 days for up to six cycles
Trial: 36239788
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and No chemotherapy
Trial: 36239858
Drug: Tumor Treating
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Treating Fields (TTFields) therapy (200 kHz)
Trial: 36239955
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both email reminders and personalized telephone outreach
Trial: 36240323
Drug: β-hydroxybutyrate (βOHB)
RxNorm normalized name: 4-hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-hydroxybutyrate (βOHB) infusion
Trial: 36240755
Drug: Fourth dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth dose of BNT162b2 vaccine
Trial: 36240755
Drug: B cell-depleting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell-depleting therapies within 12 months before vaccination
Trial: 36241982
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml subcutaneous injection of SPIO with 30-s massage
Trial: 36241982
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml intracutaneous injection of SPIO with 2-min massage
Trial: 36242742
Drug: Debridement, antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debridement, antibiotics and implant retention (DAIR) with rifampicin
Trial: 36242742
Drug: Debridement, antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debridement, antibiotics and implant retention (DAIR) without rifampicin
Trial: 39031276
Drug: Upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 15 mg (UPA15)
Trial: 36401761
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg (UPA30)
Trial: 37982966
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg (ADA)
Trial: 36244985
Drug: Neck Disability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck Disability Index (NDI-G)
Trial: 36245729
Drug: Fecal calprotectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal calprotectin measurement (≥100 μg/g)
Trial: 36245729
Drug: Fecal calprotectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal calprotectin measurement (<100 μg/g)
Trial: 36246814
Drug: 0.5 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/d ETV (Group A)
Trial: 36247059
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures assisted by two ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)
Trial: 36247059
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures assisted by four ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)
Trial: 36247059
Drug: PBM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM therapy (Dose A: 3.75 J/cm²)
Trial: 36247059
Drug: PBM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM therapy (Dose B: not specified)
Trial: 36247452
Drug: Daily steps
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily steps ≥7,500
Trial: 36247452
Drug: Daily steps
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily steps ≥10,000
Trial: 36247744
Drug: FDC formulation
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC formulation containing raloxifene 60 mg and cholecalciferol 800 IU
Trial: 36247744
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of raloxifene and cholecalciferol
Trial: 36247822
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin
Trial: 36247923
Drug: Ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg intravenously Q2W
Trial: 36248617
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID-19 vaccine (two doses)
Trial: 36248865
Drug: Neoantigen vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoantigen vaccination after local RFA treatment
Trial: 36248865
Drug: Neoantigen vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoantigen vaccination without prior RFA treatment
Trial: 36249526
Drug: Citalopram (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (single dose)
Trial: 36249705
Drug: GEM103 (Recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM103 (Recombinant Human Complement Factor H) at doses of 50 μg/eye, 100 μg/eye, 250 μg/eye, or 500 μg/eye